# BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

> **NCT04982393** · — · ACTIVE_NOT_RECRUITING · sponsor: **Alnylam Pharmaceuticals** · enrollment: 207 (actual)

## Conditions studied

- Primary Hyperoxaluria Type 1

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04982393
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-13
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982393, "BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04982393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*